Royalty Pharma plc (RPRX) Key Metrics
RPRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $35.22B
- Enterprise value
- $32.91B
- P/E (TTM)
- 32.4 10-yr median 23.0
- Forward P/E
- 29.4
- PEG ratio
- 1.34
- Price / sales
- 13.9 10-yr median 8.0
- Price / book
- 3.8 10-yr median 2.4
- EV / EBITDA
- 19.2 10-yr median 15.9
- Dividend yield
- 1.19% $0.94 a year
- Beta
- 0.41
RPRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRPRX valuation Price multiples at each fiscal year-end price.
RPRX returns How much profit the business earns on the capital it uses.
RPRX per-share figures Results divided by the shares outstanding at year-end.
RPRX financial health Debt, liquidity and how easily interest is covered.
RPRX efficiency & capital use Working capital cycle and where the cash goes.
RPRX valuation history
RPRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RPRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RPRX cash returned to shareholders
RPRX price vs earnings per share
RPRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $21.62B | $15.15B | $16.94B | $22.33B | $16.53B | $18.79B | — | — | — | — |
| Enterprise value | $29.94B | $20.99B | $21.84B | $27.01B | $27.71B | $22.90B | — | — | — | — |
| P/E ratio | 28.0 | 17.6 | 14.9 | 521.2 | 26.7 | 19.3 | — | — | — | — |
| Price / sales | 9.1 | 6.7 | 7.2 | 10.0 | 7.2 | 8.9 | — | — | — | — |
| Price / book | 3.3 | 2.2 | 2.6 | 4.0 | 1.6 | 1.3 | — | — | — | — |
| Price / free cash flow | 8.7 | 5.5 | 5.7 | 5.3 | 8.2 | 4.4 | — | — | — | — |
| Price / operating cash flow | 8.7 | 5.5 | 5.7 | 10.4 | 8.2 | 9.2 | — | — | — | — |
| EV / sales | 12.6 | 9.3 | 9.3 | 12.1 | 12.1 | 10.8 | — | — | — | — |
| EV / EBITDA | 18.3 | 13.5 | 11.6 | 63.8 | 19.4 | 12.2 | — | — | — | — |
| EV / free cash flow | 12.0 | 7.6 | 7.3 | 6.5 | 13.7 | 5.4 | — | — | — | — |
| Earnings yield | 3.6% | 5.7% | 6.7% | 0.2% | 3.7% | 5.2% | — | — | — | — |
| Free cash flow yield | 11.5% | 18.3% | 17.6% | 18.7% | 12.2% | 22.5% | — | — | — | — |
| Dividend yield | 1.7% | 2.5% | 2.1% | 1.5% | 1.7% | 2.1% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 7.4% | 4.0% | 3.9% | 2.1% | 4.6% | 2.1% | — | — | — | — |
| Share price at fiscal year-end | $38.64 | $25.51 | $28.09 | $39.52 | $39.85 | $50.05 | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $4.25 | $3.81 | $3.91 | $3.96 | $5.52 | $5.65 | $5.12 | $5.07 | $4.51 | $3.09 |
| Earnings per share | $1.38 | $1.45 | $1.88 | $0.08 | $1.49 | $2.60 | $6.63 | $3.89 | $3.42 | $0.93 |
| Operating cash flow per share | $4.45 | $4.66 | $4.96 | $3.80 | $4.86 | $5.42 | $4.71 | $4.57 | $4.00 | −$0.03 |
| Free cash flow per share | $4.45 | $4.66 | $4.96 | $7.41 | $4.87 | $11.27 | $4.71 | $4.57 | $4.00 | −$0.03 |
| Cash per share | $1.14 | $2.98 | $2.05 | $4.30 | $6.76 | $5.31 | $2.24 | $6.74 | $3.90 | $2.76 |
| Book value per share | $11.57 | $11.69 | $10.83 | $9.96 | $24.71 | $39.88 | $17.24 | $12.67 | $12.59 | $7.32 |
| Tangible book value per share | $9.92 | −$13.77 | $10.82 | $9.94 | $24.69 | $39.80 | $17.09 | $12.46 | $12.59 | $7.32 |
| Dividends per share | $0.68 | $0.63 | $0.59 | $0.59 | $0.69 | $1.06 | $2.09 | $2.30 | $2.08 | — |
| Capex per share | $0.00 | $0.00 | $3.51 | $3.61 | $0.00 | $5.85 | $4.86 | $0.76 | $6.47 | $0.00 |
| Debt per share | $15.99 | $12.82 | $10.18 | $12.60 | $33.72 | $16.24 | $17.61 | $18.41 | $19.20 | $9.72 |
| Shares outstanding | 559.6M | 594.0M | 602.9M | 564.9M | 414.8M | 375.5M | 354.2M | 354.2M | 354.2M | 607.0M |
| Change in shares outstanding | −5.8% | −1.5% | +6.7% | +36.2% | +10.5% | +6.0% | 0.0% | 0.0% | −41.7% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 11.5% | 12.8% | 18.7% | 0.5% | 4.9% | 9.3% | 44.3% | 30.8% | 27.2% | 12.4% |
| Return on invested capital (ROIC) | 6.6% | 6.9% | 9.2% | 1.0% | 3.5% | 5.2% | 22.3% | 10.5% | 6.0% | 6.1% |
| Return on assets (ROA) | 4.1% | 5.0% | 6.8% | 0.2% | 3.2% | 5.8% | 19.7% | 12.1% | 11.1% | 5.3% |
| Return on tangible assets | 4.1% | 27.7% | 6.9% | 0.3% | 3.5% | 4.6% | 18.9% | 12.2% | 10.6% | 5.4% |
| Free cash flow margin | 104.7% | 122.3% | 126.9% | 187.1% | 88.1% | 199.4% | 91.9% | 90.2% | 88.8% | −0.8% |
| Income quality (OCF / net income) | 3.23 | 3.22 | 2.63 | 50.06 | 3.26 | 2.09 | 0.71 | 1.17 | 1.17 | −0.03 |
| Financial health | ||||||||||
| Total debt | $8.95B | $7.61B | $6.14B | $7.12B | $13.99B | $6.10B | $6.24B | $6.52B | $6.80B | $5.90B |
| Cash & short-term investments | $637.5M | $1.77B | $1.23B | $2.43B | $2.80B | $1.99B | $793.2M | $2.39B | $1.38B | $1.67B |
| Net debt | $8.31B | $5.84B | $4.90B | $4.69B | $11.18B | $4.11B | $5.44B | $4.13B | $5.42B | $4.22B |
| Debt / equity | 1.38 | 1.10 | 0.94 | 1.26 | 1.36 | 0.41 | 1.02 | 1.45 | 1.52 | 1.33 |
| Debt / assets | 0.46 | 0.42 | 0.37 | 0.42 | 0.80 | 0.29 | 0.50 | 0.57 | 0.60 | 0.56 |
| Net debt / EBITDA | 5.08 | 3.75 | 2.60 | 11.07 | 7.82 | 2.18 | 1.98 | 2.26 | 3.34 | 3.95 |
| Current ratio | 0.97 | 1.44 | 7.90 | 2.19 | 16.81 | 8.76 | 2.50 | 4.50 | 7.69 | 10.10 |
| Quick ratio | 0.97 | 1.44 | 7.90 | 2.19 | 16.81 | 6.63 | 2.50 | 4.46 | 7.69 | 10.10 |
| Interest coverage | 5.1 | 5.7 | 8.0 | 1.6 | 8.6 | 10.2 | 9.8 | 4.9 | 3.8 | 3.0 |
| Working capital | −$17.2M | $548.5M | $1.11B | $1.39B | $2.71B | $2.39B | $498.7M | $2.03B | $2.56B | $2.71B |
| Invested capital | $14.79B | $12.79B | $11.43B | $10.32B | $21.43B | $19.08B | $11.55B | $8.62B | $9.88B | $8.67B |
| Tangible asset value | $8.79B | −$4.78B | $10.08B | $9.51B | $10.24B | $14.94B | $6.09B | $4.48B | $4.47B | $4.46B |
| Net current asset value | −$9.29B | −$6.08B | −$5.02B | −$4.73B | −$4.39B | −$3.43B | −$5.48B | −$4.21B | −$3.96B | −$3.02B |
| Graham number | $18.94 | $19.51 | $21.41 | $4.12 | $28.82 | $48.27 | $50.71 | $33.30 | $31.11 | $12.39 |
| Graham net-net per share | −$15.38 | −$10.25 | −$8.37 | −$8.55 | −$10.64 | −$10.05 | −$15.49 | −$12.07 | −$15.59 | −$7.16 |
| Capital allocation | ||||||||||
| Dividends paid | $378.3M | $376.5M | $358.3M | $333.3M | $285.2M | $397.0M | $739.3M | $814.4M | $735.2M | — |
| Share buybacks (net) | $1.23B | $229.7M | $304.8M | $144.1M | $479.6M | $0 | $4.3M | $0 | — | $0 |
| Dividend payout ratio | 49.1% | 43.8% | 31.6% | 778.2% | 46.0% | 40.7% | 31.5% | 59.1% | 60.8% | — |
| Dividends + buybacks / free cash flow | 64.5% | 21.9% | 22.2% | 11.4% | 37.9% | 9.4% | 44.6% | 50.3% | 51.8% | — |
| Capex / revenue | 0.0% | 0.0% | 89.8% | 91.2% | 0.0% | 103.5% | 94.9% | 15.0% | 143.4% | 0.0% |
| Capex / operating cash flow | 0.0% | 0.0% | 70.8% | 95.2% | 0.0% | 108.0% | 103.2% | 16.7% | 161.5% | — |
| Capex / depreciation | 0.00 | 0.00 | 103.20 | 359.99 | 0.02 | 95.28 | 71.95 | 8.10 | 68.86 | 0.00 |
| Stock-based compensation / revenue | 12.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.3% | — | — | — | — |
| R&D / revenue | 19.0% | 0.1% | 2.2% | 7.9% | 8.7% | 1.2% | 4.6% | 21.9% | 7.4% | 4.8% |
| SG&A / revenue | 24.1% | 10.5% | 10.6% | 10.2% | 8.0% | 8.6% | 5.7% | 3.4% | 6.7% | 0.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 69.9 | 4.0 | 4.6 | 8.6 | 8.6 | 6.7 | 23.9 | 40.4 | — | — |
| Days of inventory on hand | — | — | — | 0.0 | 264.8 | 1,039.1 | — | 51.5 | — | — |
| Days payables outstanding | 1,552.8 | 7.1 | 7.5 | 2.7 | 6.6 | 17.4 | 2.8 | 12.0 | — | — |
| Cash conversion cycle (days) | -1,482.9 | -3.1 | -2.9 | 5.8 | 266.8 | 1,028.4 | 21.1 | 79.9 | — | — |
| Receivables turnover | 5.22 | 91.72 | 79.81 | 42.65 | 42.60 | 54.47 | 15.28 | 9.04 | — | — |
| Payables turnover | 0.24 | 51.34 | 48.60 | 133.70 | 55.24 | 21.03 | 130.23 | 30.37 | — | 0.00 |
| Inventory turnover | — | — | — | 904,244,000.00 | 1.38 | 0.35 | — | 7.08 | — | — |
| Asset turnover | 0.13 | 0.13 | 0.14 | 0.13 | 0.12 | 0.13 | 0.15 | 0.16 | 0.15 | 0.18 |
| Average receivables | $455.3M | $24.7M | $29.5M | $52.5M | $53.7M | $39.0M | $118.7M | $198.6M | — | — |
| Average payables | $16.4M | $14.3M | $11.5M | $6.8M | $8.2M | $11.0M | $7.8M | $4.5M | — | $1.9M |
| Average inventory | — | — | — | $1 | $328.6M | $657.1M | — | $19.2M | — | — |
| Intangibles / total assets | 4.7% | 83.0% | 0.0% | 0.1% | 0.0% | 0.1% | 0.4% | 0.7% | 0.0% | 0.0% |
Computed from RPRX's annual financial statements (latest annual report filed February 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RPRX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Royalty Pharma traded at 28.0 times earnings, against a 10-year median of 23.0. Based on the latest twelve months, the trailing P/E is 32.4 and the forward P/E is 29.4. Royalty Pharma earned a return on equity of 11.5% and a return on invested capital of 6.6% in fiscal 2025. It ended the year with $9.0 billion of debt and $637.5 million in cash and short-term investments, net debt of $8.3 billion. It returned $1.6 billion to shareholders: $378.3 million in dividends and $1.2 billion in share buybacks, 64% of free cash flow. The share count fell 7.8% from 607.0M to 559.6M over 9 years.
See the RPRX income statement, the RPRX chart for price history, or the RPRX stock overview for the latest quote and news.
RPRX key metrics FAQ
What is Royalty Pharma's P/E ratio?
Royalty Pharma's trailing P/E ratio is 32.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 29.4. At the end of fiscal 2025 it was 28.0, compared with a 10-year median of 23.0.
What is Royalty Pharma's EV/EBITDA?
Royalty Pharma's enterprise value was 18.3 times EBITDA at the end of fiscal 2025 (enterprise value $29.9 billion, EBITDA $1.6 billion); the current EV/EBITDA is 19.2.
What is Royalty Pharma's return on equity?
Royalty Pharma's return on equity (ROE) was 11.5% in fiscal 2025: net income of $770.9 million on average shareholders' equity of $6.7 billion.
What is Royalty Pharma's ROIC?
Royalty Pharma's return on invested capital was 6.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Royalty Pharma have?
Royalty Pharma had total debt of $9.0 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.38 and $8.3 billion of net debt (5.08 times EBITDA).
What is Royalty Pharma's dividend yield?
Royalty Pharma's forward dividend yield is 1.19%. Royalty Pharma paid $378.3 million in dividends in fiscal 2025 ($0.68 per share), a payout ratio of 49.1%.
Does Royalty Pharma buy back its shares?
Yes. Royalty Pharma spent $1.2 billion on net share repurchases in fiscal 2025 Shares outstanding changed −5.8% over the year, to 559.6M..
What is Royalty Pharma's free cash flow yield?
Royalty Pharma generated $2.5 billion of free cash flow in fiscal 2025, a free cash flow yield of 11.5% on its market value at year-end ($21.6 billion).
What is Royalty Pharma's current ratio?
Royalty Pharma's current ratio was 0.97 at the end of fiscal 2025: current assets were 0.97 times current liabilities.